- Home
- NOTE vs ZURA Comparison
NOTE vs ZURA Comparison
Compare NOTE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- ZURA
- Stock Information
- Founded
- NOTE 2013
- ZURA 2022
- Country
- NOTE United States
- ZURA United States
- Employees
- NOTE N/A
- ZURA N/A
- Industry
- NOTE EDP Services
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOTE Technology
- ZURA Health Care
- Exchange
- NOTE Nasdaq
- ZURA Nasdaq
- Market Cap
- NOTE 83.1M
- ZURA 69.9M
- IPO Year
- NOTE N/A
- ZURA N/A
- Fundamental
- Price
- NOTE $4.58
- ZURA $2.00
- Analyst Decision
- NOTE Strong Buy
- ZURA Buy
- Analyst Count
- NOTE 4
- ZURA 10
- Target Price
- NOTE $29.25
- ZURA $12.67
- AVG Volume (30 Days)
- NOTE 322.8K
- ZURA 341.9K
- Earning Date
- NOTE 11-11-2025
- ZURA 11-06-2025
- Dividend Yield
- NOTE N/A
- ZURA N/A
- EPS Growth
- NOTE N/A
- ZURA N/A
- EPS
- NOTE N/A
- ZURA N/A
- Revenue
- NOTE $109,683,000.00
- ZURA N/A
- Revenue This Year
- NOTE N/A
- ZURA N/A
- Revenue Next Year
- NOTE $42.27
- ZURA N/A
- P/E Ratio
- NOTE N/A
- ZURA N/A
- Revenue Growth
- NOTE N/A
- ZURA N/A
- 52 Week Low
- NOTE $3.80
- ZURA $0.97
- 52 Week High
- NOTE $24.36
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- NOTE 37.13
- ZURA 55.46
- Support Level
- NOTE $3.80
- ZURA $1.97
- Resistance Level
- NOTE $5.48
- ZURA $2.19
- Average True Range (ATR)
- NOTE 0.59
- ZURA 0.14
- MACD
- NOTE 0.06
- ZURA -0.02
- Stochastic Oscillator
- NOTE 42.40
- ZURA 14.37
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.